Author

Ayako Bun

Observed names: AYAKO BUN, 文, 亜也子

Observed institution: Hyogo Medical University

OpenAlex ID: A5043487782

Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel

2018 · Yoshimasa Miyagawa, Kazuhiro Araki, et al. · Clinical Breast Cancer · 55

Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine

2019 · Michiko Imamura, Takashi Morimoto, et al. · Scientific Reports · 36

PDF

Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers

2019 · Yukie Fujimoto, Takahiro Watanabe, et al. · Breast Cancer · 35

Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in 18F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy

2019 · Tomoko Higuchi, Yukie Fujimoto, et al. · Annals of Surgical Oncology · 23

PDF

Improved prognosis of low baseline neutrophil‑to‑lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes

2018 · Yukie Fujimoto, Hiromi Ozawa, et al. · Molecular and Clinical Oncology · 22

PDF

Prognostic Significance of Neutrophil-to-lymphocyte Ratio in Luminal Breast Cancers With Low Levels of Tumour-infiltrating Lymphocytes

2020 · AYAKO BUN, YUKIE FUJIMOTO, et al. · Anticancer Research · 21

PDF

Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer

2020 · Yoshimasa Miyagawa, Ayako Yanai, et al. · Oncotarget · 21

PDF

C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin

2020 · ATSUSHI SATA, REIKO FUKUI, et al. · Anticancer Research · 20

PDF

Association Between FOXP3/CD8 Lymphocyte Ratios and Tumor Infiltrating Lymphocyte Levels in Different Breast Cancer Subtypes

2020 · REIKO FUKUI, YUKIE FUJIMOTO, et al. · Anticancer Research · 19

PDF

Total Lesion Glycolysis Levels as Predictive Indicators in Patients With Metastatic and Recurrent Breast Cancer Undergoing Endocrine Therapy With or Without CDK4/6 Inhibitor

2022 · HIROMI OZAWA, TOMOKO HIGUCHI, et al. · Anticancer Research · 15

PDF

High levels of serum CA15‐3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non‐pathological complete response after neoadjuvant chemotherapy

2018 · Yukie Fujimoto, Tomoko Higuchi, et al. · Journal of Surgical Oncology · 13

Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors

2022 · HARUKA KANAOKA, MASAYUKI NAGAHASHI, et al. · Anticancer Research · 9

A Single-centre, Retrospective, Observational Analysis of Fulvestrant for Recurrent/metastatic Breast Cancer According to Metastatic Site

2019 · HIROMI OZAWA, ATSUSHI SATA, et al. · Anticancer Research · 9

PDF

Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin

2023 · Ayako Bun, Masayuki Nagahashi, et al. · Breast Cancer Research and Treatment · 4

PDF

Abstract PO3-13-04: The role of sphingolipids in cancer progression and its microenvironment in breast cancer patients

2024 · Akira Hattori, Masayuki Nagahashi, et al. · Cancer Research

Abstract PO2-15-09: Immune related cell fraction in peripheral blood and outcomes of advanced breast cancer patients treated with Eribulin

2024 · Masayuki Nagahashi, Ayako Bun, et al. · Cancer Research

Abstract P5-12-02: Germline variants detected by next-generation sequencing-based multigene panel testing in patients with suspected hereditary breast cancer at a University Hospital in Japan

2023 · Yusa Atake, Masayuki Nagahashi, et al. · Cancer Research

Abstract P4-07-26: Clinical impact of tumor infiltrating lymphocytes and neutrophil-lymphocyte ratio in estrogen receptor-positive/HER2-negative breast cancer patients with high 21-gene signature recurrence scores

2022 · Haruka Kanaoka, Masayuki Nagahashi, et al. · Cancer Research

Abstract PS4-20: Low levels of interleukin-6 at baseline were significantly associated with improved overall survival of patients treated with eribulin for locally advanced or metastatic breast cancer

2021 · Ayako Bun, Natsuko Inoue, et al. · Cancer Research

Abstract P3-08-30: Low levels of metabolic tumor volume at baseline significantly associated with longer progression-free survival in patients with locally advanced or metastatic breast cancer treated with endocrine therapies

2020 · Reiko Fukui, Tomoko Higuchi, et al. · Cancer Research

Abstract P3-08-49: Baseline neutrophil-to-lymphocyte ratio and C-reactive protein predict efficacy of bevacizumab plus paclitaxel therapy for locally advanced or metastatic breast cancer

2020 · Hiromi Ozawa, Yoshimasa Miyagawa, et al. · Cancer Research

Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin

· 文, 亜也子 · Institutional Repositories DataBase (IRDB)

PDF

Works count: 22

Citation count: 302

H-index: 11

I10-index: 11